Abbott Laboratories (ABT) Stock Forecast & Price Target

$131.94 -1.66 (-1.24%)

Closing price 07/11/2025 03:58 PM Eastern

Extended Trading

$132.00 +0.06 (+0.05%)

As of 07/11/2025 07:57 PM Eastern

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
6

Buy
15

Based on 21 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 6 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for ABT.

Consensus Price Target

$143.11
8.46% Upside

According to the 21 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $143.11. The highest price target for ABT is $160.00, while the lowest price target for ABT is $127.00. The average price target represents a forecasted upside of 8.46% from the current price of $131.95.

Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

ABT Analyst Ratings Over Time

Type	Current Forecast 7/12/24 to 7/12/25	1 Month Ago 6/12/24 to 6/12/25	3 Months Ago 4/13/24 to 4/13/25	1 Year Ago 7/13/23 to 7/12/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	14 Buy rating(s)	7 Buy rating(s)
Hold	6 Hold rating(s)	4 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$143.11	$142.59	$137.94	$120.18
Forecasted Upside	8.46% Upside	4.59% Upside	8.75% Upside	15.26% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.76	2.80	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	8.46% Upside	8,633.67% Upside	10.52% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/8/2025	Evercore ISI 2 of 5 stars	Vijay Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$140.00 ➝ $145.00	+8.52%
6/16/2025	Leerink Partnrs 1 of 5 stars	M. Kratky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	Leerink Partners 1 of 5 stars		Initiated Coverage	Market Perform	$143.00	+5.61%
4/17/2025	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$133.00 ➝ $145.00	+9.98%
4/17/2025	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$132.00 ➝ $142.00	+7.70%
4/17/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$140.00 ➝ $145.00	+9.97%
4/17/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Lewis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$117.00 ➝ $127.00	-3.32%
4/17/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lawrence Biegelsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$136.00 ➝ $147.00	+11.90%
4/17/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$158.00 ➝ $159.00	+21.71%
4/17/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$135.00 ➝ $145.00	+11.76%
Get the Latest News and Ratings for ABT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors with MarketBeat's FREE daily newsletter.
4/17/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$135.00 ➝ $137.00	+5.60%
3/10/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Travis Steed Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$133.00 ➝ $150.00	+8.03%
3/4/2025	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$135.00 ➝ $160.00	+15.20%
3/4/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$138.00 ➝ $154.00	+9.70%
1/28/2025	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
1/23/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$146.00 ➝ $148.00	+25.68%
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$133.00 ➝ $138.00	+17.37%
10/17/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$115.00 ➝ $130.00	+10.34%
10/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$130.00	+14.69%
9/19/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$131.00	+14.04%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
7/21/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:19 PM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, July 9, 2025. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

Abbott Laboratories recently reported earnings per share (EPS) of $1.09, surpassing analyst expectations, indicating strong financial performance.
The company has a robust net margin of nearly 32%, suggesting efficient management and profitability.
With a current stock price around $131.56, the shares are positioned well within a market cap of approximately $228.90 billion, reflecting solid market confidence.
Abbott Laboratories has a history of consistent dividend payments, with a recent quarterly dividend of $0.59, translating to an annualized yield of about 1.78%.
Analysts have a positive outlook, with many rating the stock as a "buy" or "outperform," indicating potential for future growth.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

Despite strong earnings, the company's revenue of $10.36 billion fell slightly short of analyst expectations, which could raise concerns about future growth.
The stock has experienced fluctuations, with a one-year low of $99.71 and a high of $141.23, indicating potential volatility.
Insider selling activity, such as the recent sale of 2,600 shares by a director, may signal a lack of confidence among insiders.
The company's debt-to-equity ratio of 0.26, while relatively low, still indicates some level of leverage that could impact financial stability in adverse conditions.
Market analysts have mixed opinions, with a significant number rating the stock as a "hold," suggesting caution among some investors.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $143.11, with a high forecast of $160.00 and a low forecast of $127.00.
: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 6 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 8.46% based on their 12-month stock forecasts.
: Over the previous 90 days, Abbott Laboratories's stock had 1 upgrade by analysts.
: Abbott Laboratories has been rated by research analysts at Barclays, Evercore ISI, Jefferies Financial Group, Leerink Partners, Leerink Partnrs, Morgan Stanley, Piper Sandler, Raymond James Financial, Royal Bank Of Canada, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.
: Analysts like Abbott Laboratories less than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.76 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:ABT) was last updated on 7/12/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abbott Laboratories (ABT) Stock Forecast & Price Target